Description
A bifunctional M3 mAChR antagonist and beta2-adrenoceptor agonist (MABA) with pKi/pEC50 of 8.7/9.6 for hM3/hbeta2 respectively; shows weak effect on beta1; the first MABA compound to enter clinical trials and demonstrate proof of concept and efficacy in COPD. COPD Phase 2 Clinical